BMS-754807 was an inhibitor of both IGF-type 1 receptor and insulin receptor, and IGF-1R was highly expressed on MCL, thus BMS-754807 might be a potential target for MCL [55]. Here, IGF1R is linked to mantle cell lymphoma.